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OBJECTIVES: To compare the medical and economical impact
of four strategies in the prevention of colorectal cancer (CRC)
in France: (1) no treatment and no surveillance (reference strat-
egy); (2) chemoprevention with 325 mg daily aspirin; (3) colono-
scopic surveillance with a 3, 5 or 10-year periodicity; and (4) the
combination of the two latter strategies. METHODS: A Markov
decision model was built, following a ﬁctive 50-year-old cohort
during 30 years. Effectiveness was assessed by CRC incidence
and life expectancy. Transition probabilities were deﬁned after
an extensive review of literature. Only direct costs were consid-
ered. The various strategies were compared calculating incre-
mental cost-effectiveness ratios. Determinist and probabilistic
sensitivity analyses were carried out. RESULTS: Given an effec-
tiveness of chemoprevention of 25%, the most effective strategy
was the association chemoprevention and colonoscopic surveil-
lance. While 4248 CRC for 100,000 persons were expected in a
population without treatment or surveillance, 3228 CRC could
be avoided with this association, 2798 with a colonoscopic sur-
veillance and 1339 with the chemoprevention only. The more
effective the strategy was, the more expensive it was. Compared
with the reference strategy, the incremental cost-effectiveness
ratio of the chemoprevention was €3279 per life-year gained.
Compared with chemoprevention, colonoscopic surveillance
involved an incremental cost of €6611 per life-year gained. The
addition of a chemoprevention by aspirin among a screened pop-
ulation would result in an incremental cost-effectiveness ratio of
€22,000 per life-year saved. Moreover, in the 5000 Monte Carlo
simulations, the combination strategy was dominated by colono-
scopic surveillance in 16% of cases. CONCLUSIONS: The 3
strategies of prevention or screening has acceptable incremental
cost-effectiveness ratios according to the international standards.
Contrary to common opinion, primary prevention through
colonoscopic surveillance is cost-effective. Moreover, chemopre-
vention by aspirin appears to be an efﬁcient strategy when it is
associated to a colonoscopic surveillance.
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OBJECTIVES: Oral capecitabine is highly active drug with
favourable safety in adjuvant and metastatic colorectal cancer.
Adjuvant capecitabine is at least as effective as 5-ﬂuorouracil/leu-
covorin (5-FU/LV), with signiﬁcant superiority in relapse-free
survival and a trend towards improved disease-free and overall
survival. METHODS: We assessed the cost-effectiveness of adju-
vant capecitabine from payer (health insurance companies in
Czech Republic) and societal perspectives (including indirect
costs). We used clinical trial data and published sources to esti-
mate incremental direct and societal costs and gains in quality-
adjusted life months (QALMs). Acquisition costs were higher 
for capecitabine (99,601 CZK) than 5-FU/LV (8586 CZK), but
higher 5-FU/LV administration costs, cost of adverse events and
hospitalisation costs resulted in comparable direct costs for
capecitabine and 5-FU/LV. RESULTS: Administration costs were
signiﬁcantly higher for 5-FU/LV (by 59,500 CZK), as well as cost
of therapy for adverse effects (by 11,467 CZK). Societal costs,
including patient travel/time costs, were lower for capecitabine
group vs 5-FU/LV (cost savings 19,307 CZK), with lifetime gain
in QALMs of 9 months. Medical resource utilisation (direct
costs) are slightly higher with capecitabine vs 5-FU/LV in Czech
Republic (by 18,687). The use of a societal perspective to
measure the time and travel costs associated with the treatments
illustrates the advantage of oral over infusion treatment. Count-
ing together (direct and indirect costs) capecitabin is slightly less
costly alternative (by 624 CZK) in comparison with 5-FU/LV.
Capecitabine is also projected to increase life expectancy vs 5-
FU/LV. And from the point of view of incremental cost-utility
analysis capecitabin vs. 5-FU/LV can be considered to be domi-
nant (cost-saving and more-effective) therapy. CONCLUSIONS:
This pharmacoeconomic analysis supports the place of therapy
of capecitabine vs. 5-FU/LV in the adjuvant treatment of colon
cancer in Czech Republic.
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OBJECTIVES: To evaluate the cost-effectiveness of sorafenib plus
best supportive care (BSC) versus BSC alone in advanced renal
cell carcinoma (RCC) from the perspective of the Spanish
National Health Service. METHODS: A Markov model was
developed to project the lifetime survival and costs associated
with sorafenib plus BSC and BSC alone. The model tracked
patients with advanced RCC through three disease states—pro-
gression free survival (PFS), progression, and death. Transition
probabilities between disease states varied for each 3-month
period and were obtained from a clinical trial. Quality-Adjusted-
Life-Years (QALY) gained were used as a measure of treatment
effectiveness. Resource utilization included drug, administration,
physician visits, monitoring, and adverse events. Costs and sur-
vival beneﬁts were discounted annually at 3%. All costs were
adjusted to 2005 Euros. Scenario sensitivity analyses were con-
ducted. RESULTS: The lifetime per patient costs were €44,904
and €10,502 for sorafenib plus BSC and BSC alone, respectively.
The incremental cost-effectiveness ratio (ICER) of sorafenib plus
BSC versus BSC alone was €37,667 per QALY gained. The key
drivers of the model results were survival after progression and
PFS probabilities for both treatment groups. Sensitivity analyses
showed that the model results were robust to variance in sorafenib
and BSC treatment costs. CONCLUSIONS: Sorafenib is a cost
effective therapy in the management of advanced RCC. Sorafenib
offers a unique opportunity to prolong PFS and overall survival
in those patients, and has the potential of offer considerable value
to patients with minimal budget impact to the NHS in Spain.
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